- Home
- GTBP vs NCNA Comparison
GTBP vs NCNA Comparison
Compare GTBP & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTBP | NCNA |
|---|---|---|
| Founded | 1965 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 7.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GTBP | NCNA |
|---|---|---|
| Price | $0.66 | $3.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 63.9K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $2.78 |
| 52 Week High | $4.10 | $330.00 |
Technical Indicators
Market Signals| Indicator | GTBP | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 43.98 |
| Support Level | $0.58 | $4.10 |
| Resistance Level | $0.82 | $4.55 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 32.15 | 20.95 |
Price Performance
Historical ComparisonAbout GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.